DANGEROUS AND UNDESIRABLE DRUG INTERACTIONS OF STATINS IN PATIENTS WITH CARDIOVASCULAR DISEASE
Relevance. Antihypercholesterolemic drugs fr om the group of statins have a significant impact on the metabolism of the human body. Consideration of pharmacokinetic features of statins and drug interaction with drugs of this group is an important aspect of their safe use. Drugs administered simultaneously with statins may be inducers or inhibitors (substrates) of CYP3A4/A5 cytochrome P450 liver isoenzymes, which should be considered in daily clinical practice in the management of this category of patients The aim was to study the frequency and structure of the appointment of unwanted combinations of statins with other drugs in Semey. Materials and methods. Design: cross-sectional study. The study included 2790 outpatient records of patients with diagnosis: Coronary heart disease with concomitant hypercholesterolemia. The frequency of simultaneous administration of statins with other drugs was analyzed. We took into account the peculiarities of their interaction at the level of metabolism of cytochrome P450 CYP3 isoenzymes AND transport systems of proteins-transporters of P-glycoprotein and OATR1B and to identify potentially dangerous and significant drug combinations. Methods of descriptive statistics are used. Numerical analysis of statistical significance was not carried out due to lack of necessity. Research result. Our study revealed the presence of undesirable and dangerous combinations in the majority of patients receiving statin therapy (63.7%). The frequency of very dangerous combinations in the study was relatively low (7 cases, 0.25%). In 72.5% of cases, we did not find safety monitoring in cases wh ere it is recommended to take statins with caution and under the control of biochemical and other indicators. Conclusion. We have determined a fairly high frequency of the appointment of undesirable combinations of statins with other drugs that have competitive metabolism at the level of CYP3A, OATP1B1 and P-glycoprotein in absolute terms and compared with the data of studies conducted in developed countries.
Assem R. Makhatova 1, https://orcid.org/0000-0003-4127-7279 Raikhan E. Tuleutaeva 1, https://orcid.org/0000-0002-0462-5230 1 Department of Pharmacology them MD, Professor M.N. Mussin, NSC “Semey Medical University”, Semey s., Republic of Kazakhstan
1. Козлов С.Е., Кирищина И.А., Габдрафикова Ю.С., Солонина А.В. Рациональные комбинации лекарственных препаратов при лечении сосудистой патологии в гериатрии // Клиническая медицина. 2015. №1. С.54-59. 2. Сычев Д.А., Отделенов В.А. Межлекарствен-ные взаимодействия в практике интерниста: взгляд клинического фармаколога // Справочник поликлинического врача. – 2014. – № 12. – С. 18–21 3. Хохлов А.А., Сычев Д.А., Сироткина А.М. Аспекты безопасного применения статинов: межлекарственное взаимодействие, фармакогенети-ческие вопросы // Universum: Медицина и фармакология: электр. научный журнал. 2016. №1-2 (24). http://7universum.ru/med/article/item/2950. 4. Alreja G., Inayatullah S., Goel S., Braden G. Rhabdomyolysis caused by an unusual interaction between azithromycin and simvastatin // J Cardiovasc Dis Res. 2012 Oct; 3(4):319-22. 5. Amsden G.W., Kuye O., Wei G.C. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers // J Clin Pharmacol. 2002 Apr;42(4):444-9. 6. Bayés M., Rabasseda X., Prous J.R. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jun; 27(5):331-72. 7. Bellosta S., Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012 Nov;11(6):933-946. 8. Bellosta S., Corsini A. Statin drug interactions and related adverse reactions: an update // Expert Opin Drug Saf. 2018 Jan;17(1):25-37. 9. Boyd R.A., Stern R.H., Stewart B.H., Wu X., Reyner E.L., Zegarac E.A., Randinitis E.J., Whitfield L. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000 Jan; 40(1):91-98. 10. Campbell G., Jayakumar U., McCracken S., Bene J. A cautionary tale: delayed onset rhabdomyolysis due to erythromycin/simvastatin interaction. Age Ageing. 2007 Sep;36(5):597. 11. Chang J.H., Ly J., Plise E., Zhang X., Messick K., Wright M., Cheong J. Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice // Drug Metab Dispos. 2014. Jun;42(6):1067-73. 12. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Raza A., Schneck D.W. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects // Br J Clin Pharmacol. 2003 Jan;55(1):94-9. 13. Duan P., Zhao P., Zhang L. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs). Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4): 689-705. 14. Edwards J.E., Eliot L., Parkinson A., Karan S., MacConell L. Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects // Adv Ther. 2017 Sep;34(9):2120-2138. 15. Fernandes V., Santos M.J., Pérez A. Statin-related myotoxicity. Endocrinol Nutr. 2016 May;63(5):239-49. 16. Franz C.C., Bruggisser M., Krähenbühl S., Rätz Bravo A.E. Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole // Praxis (Bern 1994). 2011 Mar 2;100(5):273-84. 17. Guemara R., Lazarou I., Guerne I.A. Drug-induced myopathies // Rev Med Suisse. 2017 Mai 10;13(562):1013-1017. 18. Harolds J.A. Quality and Safety in Health Care, Part XXXIV: Coronary Artery Disease Secondary Prevention Medications // Clin Nucl Med. 2018 May;43(5). 331-332. 19. Heller D.J., Coxson P.G., Penko J. et al. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke // Circulation. 2017 Sep 19;136(12):1087-1098. 20. Hirota T., Ieiri I. Drug-drug interactions that interfere with statin metabolism. Expert Opin Drug Metab Toxicol. 2015;11(9):1435-47. 21. Kaleem Z., Khan J.A., Mushtaq Z., Altaf S., Javed I. Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects. Pak J Pharm Sci. 2018 May;31(3):801-806. 22. Kanathur N., Mathai M.G., Byrd R.P. Jr., Fields C.L., Roy T.M. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med. 2001 Sep;94(9):339-41. 23. Kasichayanula S., Chang M., Liu X., Shyu W.C., Griffen S.C., LaCreta F.P., Boulton D.W. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin // Adv Ther. 2012 Feb; 29(2):163-77. 24. Khan S., Khan I., Novak M., Regmi A., Difilippo W. The Concomitant Use of Atorvastatin and Amlodipine Leading to Rhabdomyolysis // Cureus. 2018 Jan 3;10(1):e2020. 25. Lee A.J., Maddix D.S. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin // Ann Pharmacother. 2001 Jan;35(1):26-31. 26. Levy R.H., Collins C. Risk and predictability of drug interactions in the elderly // Int Rev Neurobiol. 2007;81:235-51. 27. Lewin J.J. 3rd, Nappi J.M., Taylor M.H. Rhabdomyolysis with concurrent atorvastatin and diltiazem // Ann Pharmacother. 2002 Oct;36(10): 1546-1549. 28. Li D.Q., Kim R., McArthur E. et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4 // CMAJ. 2015 Feb 17;187(3):174-80. 29. Li D.Q., Kim R.B., McArthur E. et al. Statin Safety in Chinese: A Population-Based Study of Older Adults. // PLoS One. 2016 Mar 8;11(3):e0150990. 30. Martínez-Jiménez C., Cruz-Angeles J., Videa M., Martínez L.M. Co-Amorphous Simvastatin-Nifedipine with Enhanced Solubility for Possible Use in Combination Therapy of Hypertension and Hypercholesterolemia // Molecules. 2018 Aug 28;23(9). 31. Methaneethorn J., Chamnansua M., Kaewdang N., Lohitnavy M. A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans // Conf Proc IEEE Eng Med Biol Soc. 2014;2014:5711-4. 32. Molden E., Skovlund E., Braathen P. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors // Drug Saf. 2008;31(7):587-96. 33. Morival C., Westerlynck R., Bouzillé G., Cuggia M., Le Corre P. Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining // Eur J Clin Pharmacol. 2018 Apr;74(4):525-534. 34. Oztas M., Ugurlu S., Aydin O. Atorvastatin-induced dermatomyositis // Rheumatol Int. 2017 Jul; 37(7):1217-1219. 35. Patel C.G., Li L., Girgis S., Kornhauser D.M., Frevert E.U., Boulton D.W. Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole // Clin Pharmacol. 2011;3:13-25. 36. Pedersen J.K., Lydolph M.C., Somnier F., Junker P. Myopathy in a patient during simvastatin and fluconazole treatment // Ugeskr Laeger. 2016 Sep 26;178(39). 37. Prom R., Umscheid C.A., Kasbekar N., Spinler S.A. Effect of simvastatin-amiodarone drug interaction alert on appropriate prescribing // Am J Health Syst Pharm. 2013 Nov 1;70(21):1878-1879. 38. Ramkumar S., Raghunath A., Raghunath S. Statin Therapy: Review of Safety and Potential Side Effects // Acta Cardiol Sin. 2016. Nov; 32(6) :631-639. 39. Roten L., Schoenenberger R.A., Krähenbühl S., Schlienger R.G. Rhabdomyolysis in association with simvastatin and amiodarone // Ann Pharmacother. 2004 Jun;38(6):978-81. 40. Sakamoto K., Osaki M., Hozumi A., Goto H., Fukushima T., Baba H., Shindo H. Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes // BMC Musculoskelet Disord. 2011 Apr 27;12(1):82. 41. Scarfia R.V., Clementi A., Granata A. Rhabdomyolysis and acute kidney injury secondary to interaction between simvastatin and cyclosporine // Ren Fail. 2013 Aug;35(7):1056-7. 42. Selva-O'Callaghan A., Alvarado-Cardenas M., Pinal-Fernández I. et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations // Expert Rev Clin Immunol. 2018 Mar;14(3):215-224. 43. Shaik A.N., Bohnert T., Williams D.A., Gan L.L., LeDuc B.W. Mechanism of Drug-Drug Interactions Between Warfarin and Statins // J Pharm Sci. 2016 Jun;105(6):1976-1986. 44. Shin J., Pauly D.F., Pacanowski M.A., Langaee T., Frye R.F., Johnson J.A. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin // Pharmacotherapy. 2011 Oct;31(10):942-50. 45. Siedlik P.H., Olson S.C., Yang B.B., Stern R.H. Erythromycin coadministration increases plasma atorvastatin concentrations // J Clin Pharmacol. 1999 May; 39(5) : 501-4. 46. Sirtori C.R. The pharmacology of statins // Pharmacol Res. 2014 Oct;88:3-11. 47. Son H., Lee D., Lim L.A., Jang S.B., Roh H., Park K. Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine // Drug Metab Pharmacokinet. 2014; 29(2):120-8. 48. Srinivas N.R. Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil // Eur J Clin Pharmacol. 2008 Nov;64(11):1135-6. 49. Stopfer P., Giessmann T., Hohl K., Sharma A., Ishiguro N., Taub M.E., Zimdahl-Gelling H., Gansser D., Wein M., Ebner T., Müller F. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin // Clin Pharmacol Ther. 2016. Sep; 100(3):259-67. 50. Strandell J., Bate A., Hägg S., Edwards I.R. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction // Br J Clin Pharmacol. 2009 Sep;68(3):427-34. 51. Tomillero A., Moral M.A. Gateways to clinical trials // Methods Find Exp Clin Pharmacol. 2010 Jul-Aug;32(6):437-61. 52. Ucar M., Neuvonen M., Luurila H., Dahlqvist R., Neuvonen P.J., Mjörndal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid // Eur J Clin Pharmacol. 2004 Feb;59(12):879-82. 53. Uchida M., Tajima Y., Kakuni M., Kageyama Y., Okada T., Sakurada E., Tateno C., Hayashi R. Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. Drug Metab Dispos. 2018 Jan; 46(1):11-19 54. Wilke R.A., Fanciullo J. Point-Counterpoint: SLCO1B1 Genotyping for Statins // S D Med. 2017 Mar;70(3):102-104. 55. Wooten J.M. A Brief Drug Class Review: Considerations for Statin Use, Toxicity, and Drug Interactions // South Med J. 2018 Jan;111(1):39-44. 56. Yamazaki S. Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters. J Clin Pharmacol. 2018 May 3. 57. Yan M.M., Wu S.S., Ying Y.Q., Lu N., Zhong M.K. Safety assessment of concurrent statin treatment and evaluation of drug interactions in China // SAGE Open Med. 2018 Oct 11;6:2050312118798278. 58. Yan Y.L., Qiu B., Hu L.J. et al. Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: a systematic review and meta-analysis // Eur J Clin Pharmacol. 2013. Dec; 69(12): 2001-9. 59. Yang H.C., Lin C.W., Chen C.W., Chen J.J. Applying genome-wide gene-based expression quantitative trait locus mapping to study population ancestry and pharmacogenetics // BMC Genomics. 2014. Apr 29; 15 :319. References: 1. Kozlov S.E., Kirishhina I.A., Gabdrafikova Ju.S., Solonina A.V. Ratsional'nye kombinatsii lekarstvennykh preparatov pri lechenii sosudistoi patologii v geriatrii [Rational combinations of drugs in the treatment of vascular pathology in geriatrics]. Klinicheskaya meditsina [Clinical medicine]. 2015. №1. pp.54-59. [in Russian] 2. Sychev D.A., Otdelenov V.A. Mezhlekarstvennye vzaimodeistviya v praktike internista: vzglyad klinicheskogo farmakologa [Drug-drug interactions in the practice of internist: the view of clinical pharmacologist]. Spravochnik poliklinicheskogo vracha [Directory of outpatient physician]. 2014; 12: pp. 18-21. [in Russian] 3. Hohlov A.A., Sychev D.A., Sirotkina A.M. Aspekty bezopasnogo primenenija statinov: mezhlekarstvennoe vzaimodejstvie, farmakogeneticheskie voprosy [Aspects of safe use of statins: drug-drug interaction, pharmacogenetic issues]. Universum: Meditsina i farmakologiya: elektr. nauchnyi zhurnal [Medicine and pharmacology: electronic scientific journal.] 2016. №1-2 (24). http://7universum.ru/med/article/item/2950. [in Russian] 4. Alreja G., Inayatullah S., Goel S., Braden G. Rhabdomyolysis caused by an unusual interaction between azithromycin and simvastatin. J Cardiovasc Dis Res. 2012 Oct;3(4):319-22. 5. Amsden G.W., Kuye O., Wei G.C.. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol. 2002 Apr; 42(4):444-9. 6. Bayés M., Rabasseda X., Prous J.R. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72. 7. Bellosta S., Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012 Nov;11(6):933-946. 8. Bellosta S., Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018. Jan; 17(1):25-37. 9. Boyd R.A., Stern R.H., Stewart B.H., Wu X., Reyner E.L., Zegarac E.A., Randinitis E.J., Whitfield L. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000 Jan; 40(1):91-98. 10. Campbell G., Jayakumar U., McCracken S., Bene J. A cautionary tale: delayed onset rhabdomyolysis due to erythromycin/simvastatin interaction. Age Ageing. 2007 Sep;36(5):597. 11. Chang J.H., Ly J., Plise E., Zhang X., Messick K., Wright M., Cheong J. Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice. Drug Metab Dispos. 2014 Jun;42(6):1067-73. 12. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Raza A., Schneck D.W. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol. 2003 Jan;55(1):94-9. 13. Duan P., Zhao P., Zhang L. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs). Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4): 689-705. 14. Edwards J.E., Eliot L., Parkinson A., Karan S., MacConell L. Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects. Adv Ther. 2017 Sep;34(9):2120-2138. 15. Fernandes V., Santos M.J., Pérez A. Statin-related myotoxicity. Endocrinol Nutr. 2016 May;63(5):239-49. 16. Franz C.C., Bruggisser M., Krähenbühl S., Rätz Bravo A.E. Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole. Praxis (Bern 1994). 2011 Mar 2;100(5):273-84. 17. Guemara R., Lazarou I., Guerne I.A. Drug-induced myopathies. Rev Med Suisse. 2017 Mai 10;13(562):1013-1017. 18. Harolds J.A. Quality and Safety in Health Care, Part XXXIV: Coronary Artery Disease Secondary Prevention Medications. Clin Nucl Med. 2018 May;43(5). 331-332. 19. Heller D.J., Coxson P.G., Penko J. et al. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke. Circulation. 2017 Sep 19;136(12):1087-1098. 20. Hirota T., Ieiri I. Drug-drug interactions that interfere with statin metabolism. Expert Opin Drug Metab Toxicol. 2015;11(9):1435-47. 21. Kaleem Z., Khan J.A., Mushtaq Z., Altaf S., Javed I. Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects. Pak J Pharm Sci. 2018 May;31(3):801-806. 22. Kanathur N., Mathai M.G., Byrd R.P. Jr, Fields C.L., Roy T.M. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med. 2001 Sep;94(9):339-41. 23. Kasichayanula S., Chang M., Liu X., Shyu W.C., Griffen S.C., LaCreta F.P., Boulton D.W. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012 Feb;29(2):163-77. 24. Khan S., Khan I., Novak M., Regmi A., Difilippo W. The Concomitant Use of Atorvastatin and Amlodipine Leading to Rhabdomyolysis. Cureus. 2018 Jan 3;10(1):e2020. 25. Lee A.J., Maddix D.S. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother. 2001. Jan; 35(1): 26-31. 26. Levy R.H., Collins C. Risk and predictability of drug interactions in the elderly. Int Rev Neurobiol. 2007;81:235-51. 27. Lewin J.J. 3rd, Nappi J.M., Taylor M.H. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother. 2002. Oct;36(10): 1546-1549. 28. Li D.Q., Kim R., McArthur E. et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. CMAJ. 2015 Feb 17;187(3):174-80. 29. Li D.Q., Kim R.B., McArthur E. et al. Statin Safety in Chinese: A Population-Based Study of Older Adults. PLoS One. 2016 Mar 8;11(3):e0150990. 30. Martínez-Jiménez C., Cruz-Angeles J., Videa M., Martínez L.M. Co-Amorphous Simvastatin-Nifedipine with Enhanced Solubility for Possible Use in Combination Therapy of Hypertension and Hypercholesterolemia. Molecules. 2018 Aug 28;23(9). 31. Methaneethorn J., Chamnansua M., Kaewdang N., Lohitnavy M. A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans. Conf Proc IEEE Eng Med Biol Soc. 2014;2014:5711-4. 32. Molden E., Skovlund E., Braathen P. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Drug Saf. 2008;31(7):587-96. 33. Morival C., Westerlynck R., Bouzillé G., Cuggia M., Le Corre P. Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining. Eur J Clin Pharmacol. 2018 Apr;74(4):525-534. 34. Oztas M., Ugurlu S., Aydin O. Atorvastatin-induced dermatomyositis. Rheumatol Int. 2017 Jul;37(7):1217-1219. 35. Patel C.G., Li L., Girgis S., Kornhauser D.M., Frevert E.U., Boulton D.W. Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clin Pharmacol. 2011;3:13-25. 36. Pedersen J.K., Lydolph M.C., Somnier F., Junker P. Myopathy in a patient during simvastatin and fluconazole treatment. Ugeskr Laeger. 2016 Sep 26;178(39). 37. Prom R., Umscheid C.A., Kasbekar N., Spinler S.A. Effect of simvastatin-amiodarone drug interaction alert on appropriate prescribing. Am J Health Syst Pharm. 2013 Nov 1;70(21):1878-1879. 38. Ramkumar S., Raghunath A., Raghunath S. Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiol Sin. 2016. Nov;32(6): 631-639. 39. Roten L., Schoenenberger R.A., Krähenbühl S., Schlienger R.G. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother. 2004 Jun;38(6):978-81. 40. Sakamoto K., Osaki M., Hozumi A., Goto H., Fukushima T., Baba H., Shindo H. Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes. BMC Musculoskelet Disord. 2011 Apr 27;12(1):82. 41. Scarfia R.V., Clementi A., Granata A. Rhabdomyolysis and acute kidney injury secondary to interaction between simvastatin and cyclosporine. Ren Fail. 2013. Aug;35(7):1056-7. 42. Selva-O'Callaghan A., Alvarado-Cardenas M., Pinal-Fernández I. et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018 Mar;14(3):215-224. 43. Shaik A.N., Bohnert T., Williams D.A., Gan L.L., LeDuc B.W. Mechanism of Drug-Drug Interactions Between Warfarin and Statins. J Pharm Sci. 2016 Jun;105(6):1976-1986. 44. Shin J., Pauly D.F., Pacanowski M.A., Langaee T., Frye R.F., Johnson J.A. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. Pharmacotherapy. 2011 Oct;31(10):942-50. 45. Siedlik P.H., Olson S.C., Yang B.B., Stern R.H. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol. 1999 May;39(5):501-4. 46. Sirtori C.R. The pharmacology of statins. Pharmacol Res. 2014 Oct;88:3-11. 47. Son H., Lee D., Lim L.A, Jang S.B., Roh H., Park K. Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine. Drug Metab Pharmacokinet. 2014;29(2):120-8. 48. Srinivas N.R. Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil. Eur J Clin Pharmacol. 2008 Nov;64(11):1135-6. 49. Stopfer P., Giessmann T., Hohl K., Sharma A., Ishiguro N., Taub M.E., Zimdahl-Gelling H., Gansser D., Wein M., Ebner T., Müller F. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin. Clin Pharmacol Ther. 2016 Sep;100(3):259-67. 50. Strandell J., Bate A., Hägg S., Edwards I.R. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol. 2009 Sep;68(3):427-34. 51. Tomillero A., Moral M.A. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jul-Aug;32(6):437-61. 52. Ucar M., Neuvonen M., Luurila H., Dahlqvist R., Neuvonen P.J., Mjörndal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol. 2004 Feb;59(12):879-82. 53. Uchida M., Tajima Y., Kakuni M., Kageyama Y., Okada T., Sakurada E., Tateno C., Hayashi R. Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. Drug Metab Dispos. 2018 Jan;46(1):11-19. 54. Wilke R.A., Fanciullo J. Point-Counterpoint: SLCO1B1 Genotyping for Statinsю S D Med. 2017 Mar;70(3):102-104. 55. Wooten J.M. A Brief Drug Class Review: Considerations for Statin Use, Toxicity, and Drug Interactions. South Med J. 2018 Jan;111(1):39-44. 56. Yamazaki S. Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters. J Clin Pharmacol. 2018 May 3. 57. Yan M.M., Wu S.S., Ying Y.Q., Lu N., Zhong M.K. Safety assessment of concurrent statin treatment and evaluation of drug interactions in China. SAGE Open Med. 2018. Oct 11;6:2050312118798278. 58. Yan Y.L., Qiu B., Hu L.J. et al. Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2013 Dec;69(12):2001-9. 59. Yang H.C., Lin C.W., Chen C.W, Chen J.J. Applying genome-wide gene-based expression quantitative trait locus mapping to study population ancestry and pharmacogenetics. BMC Genomics. 2014 Apr 29;15:319.
Number of Views: 257

Key words:

Bibliography link

Махатова А.Р., Тулеутаева Р.Е. Опасные и нежелательные межлекарственные взаимодействия статинов у больных кардиоваскулярной патологии // Наука и Здравоохранение. 2019. 2 (Т.21).С. 55-66. Makhatova A.R., Tuleutaeva R.E. Dangerous and undesirable drug interactions of statins in patients with cardiovascular disease // Nauka i Zdravookhranenie [Science & Healthcare]. 2019, (Vol.21) 2, pp. 55-66. Махатова Ә.Р., Тулеутаева Р.Е. Кардиоваскулярлы жүйенің патологиясы бар науқастарда статиндердің қауіпті және жағымсыз дәрі-дәрмектік өзара әрекеттесуі // Ғылым және Денсаулық сақтау. 2019. 2 (Т.21). Б. 55-66.

Авторизируйтесь для отправки комментариев